Skip to content
Clinical Trials – home

Stift Carlanderska Sjukhuset

Verified siteinfoFast reply

Sweden Carlandersparken 1, 412 55 Gothenburg, Sweden

  • 3 trials recruiting
  • Type 2 diabetes mellitus · Obesity · Arteriosclerosis
  • Adults and children

About Specializations

Stift Carlanderska Sjukhuset in Gothenburg, Sweden specialises in clinical trials of conditions such as Type 2 diabetes mellitus, Obesity, Arteriosclerosis, COVID-19, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases Research

At Stift Carlanderska Sjukhuset, clinical trials in cardiovascular diseases focus on people at elevated risk of major heart and blood vessel events, including those with established risk factors but no prior heart attack or stroke. The studies are designed to test new approaches that may help prevent serious outcomes and improve long-term heart health.

  • Preventing major adverse cardiovascular events in high-risk adults
  • Reducing the risk of heart attack, stroke, and related complications
  • Evaluating treatments for primary prevention of atherosclerotic cardiovascular disease

These trials mainly explore whether newer therapies can lower the chance of future coronary heart disease events and support better prevention strategies in patients with significant cardiovascular risk.

Nutritional and Metabolic Diseases Research

The site also conducts studies in nutritional and metabolic diseases, especially type 2 diabetes, obesity, and related conditions such as heart failure with preserved or mildly reduced ejection fraction. This research looks at how treatments may improve weight, blood sugar control, and broader cardiometabolic health.

  • Improving outcomes in type 2 diabetes and early diabetes care
  • Testing therapies for obesity and overweight with diabetes
  • Studying treatments for heart failure linked to obesity and metabolic disease

Overall, the research is aimed at finding more effective ways to manage metabolic disorders while also lowering the risk of heart-related complications in people with diabetes mellitus type II and related conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Carlandersparken 1412 55 GothenburgSweden
Recruiting now
3 trials
Conditions studied
11
Partner status
Verified site

More sites in GothenburgSweden

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

10 clinical trials

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Coeliac disease

Recruiting

Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Methyl (E,6S)-7-[[1-[2-(2-Ethylbutylamino)-2-Oxoethyl]-2-Oxopyridin-3-Yl]Amino]-6-[(3-Methylimidazole-4-Carbonyl)Amino]-7-Oxohept-2-Enoate
  • Sponsor:Dr. Falk Pharma GmbH

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Type 2 diabetes mellitus+1

Not recruiting

Study on the Effectiveness of Survodutide for Weight Loss in Patients with Type 2 Diabetes and Obesity

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim Espana S.A.

Obesity

Not recruiting

Study on the Effectiveness of Survodutide for Weight Loss in Adults with Obesity Without Diabetes

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

Comparison of dapagliflozin versus metformin treatment in patients with early stage type 2 diabetes to evaluate survival and complications

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin Propanediol
  • Sponsor:Uppsala University

Dermatitis atopic+1

Not recruiting

Study on the Effect of a New Moisturiser with Paraffin and Liquid Paraffin on Preventing Eczema Relapse in Children

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Glycerol
  • Sponsor:Aco Hud Nordic AB

COVID-19

Not recruiting

Study on the Effectiveness and Safety of Bemnifosbuvir for High-Risk COVID-19 Patients

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nirmatrelvir
  • Sponsor:Atea Pharmaceuticals Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.